Weekly Cardiology Research Analysis
This week’s cardiology literature highlighted both practice-changing randomized trials and important mechanistic/therapeutic signals. A safety signal from a phase‑2 NPR1 agonist trial (XXB750) cautions further receptor‑activating biologics in heart failure, while prespecified SELECT analyses show semaglutide reduces MACE in patients at high risk of liver fibrosis. A pragmatic multicenter RCT (PRO‑TAVI) supports deferring PCI in selected TAVI candidates without worsening 1‑year major outcomes, su
Summary
This week’s cardiology literature highlighted both practice-changing randomized trials and important mechanistic/therapeutic signals. A safety signal from a phase‑2 NPR1 agonist trial (XXB750) cautions further receptor‑activating biologics in heart failure, while prespecified SELECT analyses show semaglutide reduces MACE in patients at high risk of liver fibrosis. A pragmatic multicenter RCT (PRO‑TAVI) supports deferring PCI in selected TAVI candidates without worsening 1‑year major outcomes, suggesting shifts in revascularization workflows.
Selected Articles
1. The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial.
In a multicenter phase‑2 randomized trial (n=136), the NPR1 agonist antibody XXB750 unexpectedly increased NT‑proBNP and reduced cGMP at 16 weeks, and was associated with higher rates of death or worsening heart failure compared with sacubitril/valsartan and placebo, prompting early trial termination.
Impact: Provides a clear negative clinical signal for NPR1‑activating biologics in heart failure, redirecting development priorities and underscoring the need for deeper mechanistic understanding before advancing receptor‑activating therapies.
Clinical Implications: NPR1 agonist therapy should not be used outside clinical trials; clinicians and developers should prioritize mechanistic studies and cautious safety monitoring for natriuretic peptide pathway interventions.
Key Findings
- XXB750 arms showed an NT‑proBNP increase (ratio 1.34) and cGMP decrease (ratio 0.77) at 16 weeks.
- Death or worsening heart failure events were more frequent with XXB750 (25%) versus sacubitril/valsartan (8%) and placebo (0%), leading to early termination.
2. Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
A prespecified secondary analysis of SELECT found semaglutide reduced MACE by 26% in patients with FIB‑4 ≥1.3 (HR 0.74) and improved fatty liver index over 104 weeks. Benefits were consistent across FIB‑4 thresholds, supporting cardiometabolic benefit particularly in patients at elevated fibrosis risk.
Impact: Strengthens evidence that GLP‑1 receptor agonists confer cardiovascular protection in non‑diabetic obese/ASCVD populations and suggests liver fibrosis risk (FIB‑4) as a useful enrichment marker for benefit.
Clinical Implications: Consider incorporating FIB‑4/fatty liver assessments into cardiometabolic risk stratification to prioritize semaglutide therapy for patients with ASCVD and elevated fibrosis risk, pending guideline integration.
Key Findings
- Semaglutide reduced MACE by 26% in patients with FIB‑4 ≥1.3 (HR 0.74; 95% CI 0.63–0.88).
- Semaglutide produced a 28% greater decrease in fatty liver index versus placebo over 104 weeks (P<0.0001).
3. Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial.
In 466 TAVI candidates with coronary disease, randomization to PCI deferral versus routine pre‑TAVI PCI demonstrated non‑inferiority for the 1‑year composite of death, MI, stroke, and major bleeding (24% vs 26%; HR 0.89; non‑inferiority p=0.0008), supporting a conservative, individualized revascularization approach in selected patients.
Impact: Provides pragmatic randomized evidence to change the timing of coronary revascularization around TAVI, with potential to reduce procedural burden and bleeding without increasing 1‑year major events.
Clinical Implications: For selected stable coronary disease in TAVI candidates, clinicians may reasonably defer PCI and individualize revascularization planning, balancing anatomy, symptoms, and procedural risks.
Key Findings
- Deferral of PCI met non‑inferiority against pre‑TAVI PCI for the 1‑year composite endpoint (24% vs 26%; HR 0.89; non‑inferiority p=0.0008).
- Median age 81 years and stratification by proximal LAD disease reflect real‑world TAVI demographics.